Haemophilia

Article	Citations
AHP Oral Abstracts	47
The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti‐FVIII antibody	40
The detrimental effects of iron to the joint; aggravation by inflammation	37
Effectiveness of therapeutic exercise and cognitive‐behavioural therapy combined protocol on functionality, pain and joint health in people with haemophilia: Secondary analysis of a controlled trial	34
The importance and evolution of bleeding disorder registries	33
Recommendations for Psychosocial Support during Gene Therapy: Results From an EAHAD Interdisciplinary Roundtable	33
13th BIC International Conference	33
New Treatment in Haemophilia: Challenges, Controversies and Uncertainties	32
A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV?	31
Competence and Confidence: An Evaluation of Physiotherapists' Knowledge and Self‐Perception About Physical Activity and Exercise in Patients With Haemophilia	30
Developing a Two‐Sided Decision Box to Facilitate Shared Decision‐Making for Switching From Conventional to Pharmacokinetic‐Tailored Prophylaxis in Haemophilia	30
CCS_Book of abstracts	28
Platelet Hyperreactivity May Contribute to Thrombotic Complications in Afibrinogenemia: A Case‐Based Observation	27
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound	26
Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review	25
Haemophilia B, severe childhood obesity and other extra‐haematological features associated with similar 4Mb‐deletions on Xq27: Clinical findings, molecular insights and literature update	24
Wearable activity trackers in young people with haemophilia: What needs to be considered?	21
Reinvestigation of unidentified causative variants in FXI‐deficient patients: Focus on gene segment deletions	21
Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study	20
Initial von Willebrand factor antigen values in adolescent females predict future values	20
PUBLICATION ONLY ABSTRACTS	19
Comparison of the kinematic analysis of indoor and outdoor gait in people with haemophilia and total knee replacement	19
Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy	19
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience	18
Clinical outcomes of low‐dose pharmacokinetic‐guided extended half‐life versus low‐dose standard half‐life factor VIII concentrate prophylaxis in haemophilia A patients	18

Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries	17
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow‐up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)	17
	17
	17
The UK Infected Blood Inquiry: A Personal Reflection	17
Knowledge gaps in health‐related quality of life research performed in children with bleeding disorders – A scoping review	17
Severe Congenital Factor X Deficiency in an Indian Child With a Concomitant Novel ITGA2 Variant	16
Towards achieving a haemophilia‐free mind	16
People With Haemophilia as Data Coordinators: An Analysis of the Ethics and Feasibility of Self‐Management With Personal Health Records	16
Cost Analysis of Radioactive Versus Arthroscopic Synovectomy in Haemophilia: A Brazilian Modelling Approach	16
Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies	16
Real world management of individuals with severe FXI deficiency and its impact on clinical outcomes: Experience from a haemophilia treatment centre	16
Development of the World Federation of Hemophilia Shared Decision‐Making Tool	15
Occurrence of familial Mediterranean fever in haemophilia patients	15
Validating the Online Self‐Administered Bleeding Assessment Tool (Self‐BAT) as a Screening Tool for Bleeding Disorders	15
Emicizumab and asparaginase, A first experience to share	15
Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency	15
AUTHOR INDEX	15
Factor XIII levels correlate with fibrinogen concentrations in patients with venous malformations	15
Clinical Course of Residual Flexion Contracture After Total Knee Arthroplasty in Patients With Haemophilic Arthropathy	15
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective	15
Profiling of Anti‐FVIII Antibodies in Acquired Haemophilia A: ‘Insights into Domain Specificity, Isotype Variability, and Clinical Correlations’	15
Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes	15
Assessment of rare bleeding disorders in adolescents with heavy menstrual bleeding	15
Development of a target product profile (TPP) for haemophilia point‐of‐care (POC) diagnostic devices for low‐resource countries and remote settings	14
A 10‐year single‐institution retrospective review of treatment for acquired hemophilia A	14
P2RY12‐Related Platelet Dysfunction in an Indian Child: Unravelling the Diagnostic Enigma of Suspected Platelet Storage Pool Disorder	14
Tandem and inverted duplications in haemophilia A: Breakpoint characterisation provides insight into possible rearrangement mechanisms	14
Factors associated with physical activity in young people with haemophilia A on prophylaxis	14
Lifetime Cost‐Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis	14
The lived experience of mothers of children with haemophilia in Jordan: A phenomenological study	13
IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy	13
Haemophilia Care in India: A Multicentre Cross‐Sectional Analysis From the World Bleeding Disorders Registry Benchmarking Across Global Gross National Income Strata	13
A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials	13
Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project	13
Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study	13
Acquired Haemophilia A and COVID‐19 mRNA Vaccine Tozinameran: Analysis of Cases Registered in the French PharmacoVigilance Database	13
Comprehensive Assessment of the Transition to Efanesoctocog Alfa Prophylaxis in a Paediatric Haemophilia A Cohort	13
Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review	13
Correction to “Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry”	13
Artificial Intelligence Applications in Haemophilia Care: A Narrative Review of the Literature	13
	12
Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients	12
The Swiss Haemophilia Registry–Report From the First 8 Years	12
Patient‐Reported Outcome Measures and Clinical Performance in Hemophilia: Implications for Person‐Centered Care	12
Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A	12
Defining the Role of Nurses in Gene Therapy for Haemophilia	12
Alleviated bleeding phenotypes in a child with severe haemophilia A and thalassemia disease	12
Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers	11
Management of Persons With Haemophilia Requiring Antithrombotic Therapy: A Canadian Modified Delphi Consensus Study	11

F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A	11
Correction to “Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Hemophilia A”	11
Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study	11
Reduced‐Dose versus Standard‐Dose Emicizumab for Haemophilia A: A Retrospective Cohort Study	11
	11
Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi‐criteria decision analysis	11
Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience	11
Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real‐Life Case Series and Literature Review	11
Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies	10
Postpartum Acquired Hemophilia A in Two Women With Previously Undiagnosed Carrier Status for von Willebrand Disease Type 2N and Heterozygous p.R854Q Mutation	10
Clotting Factor Concentration During Menstrual Phases in Women With and Without Heavy Menstrual Bleeding: A Systematic Review and Meta‐Analysis	10
Physical Activity Awareness and Understanding of Treatment Protection Among People With Haemophilia and Their Caregivers in Central Europe	10
Book of Abstracts	10
Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis	10
Assessing the Impact of the 2021 VWD Guidelines on the Diagnosis/Management of Low VWF Patients	10
Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia B	10
Systematic Literature Review of Outcomes Associated With Adherence to Haemophilia Drug Therapy	10
Ankle joint distraction is a promising alternative treatment for patients with severe haemophilic ankle arthropathy	10
The haemophilia joint health score for the assessment of joint health in patients with haemophilia	10
Efficacy, safety and bioequivalence of the human‐derived B‐domain‐deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients	10
The state of oral health in patients with haemophilia in the Netherlands	10
Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen	10
Performance on the iSTEP and 10 m‐ISWT in boys with haemophilia	10
Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity	10
Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health	9
Author Index	9
Democratisation of physiotherapy for people with haemophilia	9
TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab	9
Diagnosis and management of factor XI alloinhibitors in patients with congenital factor XI deficiency—A large single‐centre experience	9
Real‐World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study	9
Scientific Review of the UK Infected Blood Inquiry Report: A Personal Reflection	9
Patient‐centred research agenda for females with bleeding disorders	9
Integrating Next‐Generation Sequencing Into Routine Molecular Diagnosis of Inherited Coagulation Factor Deficiencies: Real‐World Data From Spanish Patients	9
Clotting factor activity levels and bleeding risk in people with haemophilia playing sports	9
Retraction	9
Commentary: The Infected Blood Inquiry in the United Kingdom—Let the Dust Settle	9
The role of the specialist nurse in comprehensive care for bleeding disorders in Europe: An integrative review	9
Does the method of telehealth delivery affect the physiotherapy management of adults with bleeding disorders? A comparison of audioconferencing and videoconferencing	9
Breaking barriers in haemophilia A care: One‐year real‐world experience with emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal	9
Identifying performance‐based outcome measures of physical function in people with haemophilia (IPOP)	8
Perceptions and Recommendations Regarding Haemophilia B Gene Therapy: A Multistakeholder View From Patients, Caregivers and Healthcare Professionals	8
Treatment of haematuria with factor concentrate in people with haemophilia is associated with low rates of complications	8
Bone marrow oedema syndrome as a cause of chronic knee pain in a person with severe Haemophilia A	8
Enhancing Engagement to Support Shared Decision Making Within Haemophilia: Development of Materials for People With Haemophilia, Caregivers and Healthcare Professionals	8
Dental Neglect by Individuals With Haemophilia: Clinical Challenges and Solutions	8
	8
European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice	8
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B	8
Five new F10 variants in hereditary factor x deficiency detected by high‐throughput sequencing	8
Accuracy and clinical role of digital templating for total knee arthroplasty performed on haemophilic knees	8
Haemophilia Joint Health Score Ranges Across the Lifespan: Variation by Haemophilia Type and Severity	8
Validity and reliability test of the Indonesian version of the PedHALshort questionnaire	8
COMMITTEE LIST	8
Experiences and Needs Regarding Information Provision in Children With Haemophilia: A Qualitative Study on Caregivers’ and Healthcare Providers’ Perspectives	8
Harmonizing patient‐reported outcome measurements in inherited bleeding disorders with PROMIS	8
Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐ce	8
Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature	8
HRQoL and psychosocial aspects of burden on caregivers to children with moderate or severe von Willebrand disease	8
Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B	7
Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan	7
Abstract	7
Comprehensive Analysis of Surgical Interventions for Musculoskeletal Disorders in Patients With Bleeding Disorders: Report From a Subspecialty Unit in a Developing Country	7
Psychophysical assessment of pain in adults with moderate and severe haemophilia: A cross‐sectional study	7
Issue Information	7
Clinical and Economic Burden of Patients With Haemophilia A and B in France: Analysis of a Nationwide Claims Database	7
Modulation of Haemostatic Balance in Combined von Willebrand Disease and Antithrombin Deficiency: A Comprehensive Family Study	7
Prophylactic Factor Replacement Versus on‐Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10‐Year Follow‐up	7
Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State	7
Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience	7
UKNEQAS Blood Coagulation Factor Nine (FIX) Gene Therapy Supplementary Exercise 2025	7
Efficacy and Safety of Aspiration and Intra‐Articular Injection of Tranexamic Acid in Acute Knee Hemarthrosis of Adult Haemophilic Patients: A Randomized Clinical Trial Study	7
Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences	7
Morphological Variations in Haemophilic Knee Arthropathy: Surgical Implications for Total Knee Arthroplasty Component Selection and Bone Preparation	7
Sexual functioning in men with haemophilia: Data from the haemophilia in the Netherlands‐6 study	7
Haemophilia care in Asia: Learning from clinical practice in some Asian countries	7
Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments	7
Committee List	7
Bridging the gap: Survey highlights challenges and solutions in outreach and identification of people with inherited bleeding disorders	7
Deciphering a novel complex inversion affecting F8 in a family with severe haemophilia A by optical genome mapping	7
Haemophilic Elbow Arthropathy: Mechanisms, Management and Future Perspectives	7

Radiological Stage of Hemophilic Arthropathy of Knee Does Not Correlate With Clinical Variables	7
Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series	6
Acquired haemophilia A: A 15‐year population‐based review of incidence rate, patient demographics and treatment outcomes	6
Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy	6
Central Nervous System Bleeding in Children With Haemophilia in Limited Resource	6
Abstract	6
Prevalence and Impact of Heavy Menstrual Bleeding in Women With von Willebrand Disease Across Age Groups: A Retrospective Study	6
In vitro evaluation of global coagulation potentials in the co‐presence of plasma‐derived factors Viia/X products (Byclot®) and emicizumab in patients with haemophilia A and inhibitors and	6
Identification and Analysis of Mitochondria‐Related Proteins in Haemophilic Arthritis Synovial Membranes Based on Proteomic Analysis	6
Coagulation Factor Consumption and Medium‐ to Long‐Term Outcomes of Achilles Tendon Lengthening With and Without External Fixation in Haemophilia	6
Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry	6
Health‐Related Quality of Life Among Female Carriers of Haemophilia and Non‐Carriers in a Colombian Population	6
Low vitamin C status and hypermobility‐related disorders in patients with bleeding disorder of unknown cause	6
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A	6
Research Letter: Patient Attitudes Towards Haemophilia Gene Therapy at a US Haemophilia Treatment Center	6
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy	6
Diagnosis and treatment of von Willebrand disease in 2024 and beyond	6
Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group	6
POSTER ABSTRACTS	6
Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience	6
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B	6
A Psychometric Analysis of the Haemophilia Quality of Life Questionnaire for Adults Physical Health Subscale and Total Scores: Data From the Phase 3 XTEND‐1 Trial in Patients With Severe Haemophilia A	6
A national assessment of standards of care for inherited bleeding disorders in Canada	6
Methylome analysis for haemophilia A intron 22 inversion patients with and without inhibitors: A pilot study	6
Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia	6
Nonneutralizing Antibodies in Haemophilia A Patients: To be Ignored or Not to be!	6
	6
Real‐World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database	6
The effect of a virtual child disease management programme on burden and social adjustment of caregivers of children with coagulation factor deficiencies	5
Monitoring Extended Half‐Life Factor VIII and IX Concentrates: Performance in Routine Clotting‐and Thrombin Generation Assays	5
Acquired bleeding disorders	5
Qualification Criteria of Gene Therapy for Haemophilia—Opinion of the EAHAD Gene Therapy Working Group	5
Depression and anxiety in persons with Von Willebrand disease	5
The Humanitarian and Medical Crisis in Palestinian Territories: The Plight of Patients With Congenital Bleeding Disorders and Health Care Under Siege	5
Invited Medical Presentation Abstracts	5
Milds Matter—Feasibility of Emicizumab Prophylaxis in Mild Hemophilia	5
Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding	5
Supporting Patient‐Centred Decisions on Gene Therapy for Haemophilia A: A Conceptual Model	5
Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A	5
Race and ethnicity and the success of immune tolerance induction among people with severe haemophilia A in the United States	5
Molecular spectrum of inherited FVII deficiency in North India revealed a recurrent variant with a founder effect	5
	5
Evaluation of Access to Care for Women Carriers of Haemophilia in Haemophilia Treatment Centres: A Multinational Experience	5
Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 1	5
HEAD‐US Score and Cartilage Biomarkers in Patients With Severe Haemophilia A Who Receive Low‐Dose Factor VIII Prophylaxis	5
Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD	5
Weight‐Bearing Lunge Test in Young Patients With Haemophilia and Limited Joint Damage: Reliability and Functional Associations for Ankle Assessment	5
Desmopressin Response in Children With Platelet Disorders May Depend on the Presence of a Genetic Cause When Response Is Measured With Von Willebrand Activity and Platelet Function Analyser	5
Cross‐Sectional Survey of Haemophilia Treatment Centres (HTCs) in India: Towards a Context‑Sensitive Stratification Model	5
Differences and similarities in patient‐reported outcomes among men and women with haemophilia	5
Psychological and cognitive factors involved in decision‐making process of haemophilia carriers in reproductive choices	5
Association of factor expression levels with annual bleeding rate in people with haemophilia B	5
Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment	5
Defining success in haemophilia care – Are we doing it right?	5
Haemostatic Prophylaxis and Colonoscopy Outcomes in Patients With Bleeding Disorders: An Update	5
Issue Information	5
EAHAD statement on the ISTH clinical practice guideline for treatment of congenital haemophilia A and B	5
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross‐se	4
Factor VIII Activity and Factor VIII Inhibitors Can Be Measured Accurately in Plasma Containing Mim8 by Using Specific Chromogenic Assays	4
Effects of physical therapy on health‐related quality of life in patients with haemophilia: A systematic review and meta‐analysis	4
Targeting a higher plasma VWF level at time of delivery in pregnant individuals with von Willebrand disease: Outcomes at a single‐institution cohort study	4
Early changes in bleeding perception and quality of life in children and adolescents receiving emicizumab prophylaxis for severe haemophilia A without inhibitor	4
Iron overload causes macrophages to produce a pro‐inflammatory phenotype in the synovium of hemophiliac arthritis via the acetyl‐p53 pathway	4
Women and girls’ participation in haemophilia clinical trials	4
Longitudinal observations of TFPI levels in paediatric Haemophilia A patients	4
Interferences by factor VIII and lupus anticoagulant in the modified one‐stage assay for emicizumab	4
Tissue Transfer in the Management of Wound Complications in Patients With Haemophilia: Report of Two Cases	4
Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single‐arm, open‐label study	4
Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays	4
Evaluation of the care pathway in the context of the dispensing of emicizumab (Hemlibra) in community and hospital pharmacies in France: A patient satisfaction survey	4
Issue Information	4
Severe Bleeding Disorders Patients Who Developed Excess Weight Gain During the COVID‐19 Pandemic Revert to Their Pre‐Pandemic Weight and BMI Percentiles	4
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Gro	4
Male Range of Motion Norms in the Haemophilia Joint Health Score Underrepresent the Severity of Joint Damage in Females	4
Real‐world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non‐interventional, post‐authorization safety study	4
Immune gene polymorphisms associated with poor response to platelet transfusion and recombinant factor VII administration in Glanzmann thrombasthenia	4
Real‐world data for the use of emicizumab in haemophilia A patients with inhibitors – First nationwide report from Korea	4
Review of interventions and effectiveness for heavy menstrual bleeding in women with moderate and severe von Willebrand disease	4
ImpaHCta—Haemophilia Carriers Quality of Life Assessment	4
Factor X and Combined Factor VIIa/Factor X Augment Coagulation Potential in a Plasma Model of Tissue Factor Pathway Inhibitor‐Reduced Haemophilia State	4
Haemophilia A and B – evaluation of the Swedish prophylactic regimen by magnetic resonance imaging	4
Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study	4
Specialist training in thrombosis and haemostasis across Europe: From aspirations to actions	4
The impact of emicizumab on the clinical validation of new therapies for haemophilia A	4
Preference of treatment characteristics among people with haemophilia or their caregivers, and physicians in the Japanese healthcare environment	4
Non‐surgical correction of knee flexion deformity in persons with haemophilia: A staged multidisciplinary approach	4
Guidance for the antithrombotic management of persons with haemophilia and cardiovascular disease	4
Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis	4
AUTHOR INDEX	4
Use of an Oral Health‐Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders	4
Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe	4
Severe haemorrhages leading to a diagnosis of rare bleeding disorder occur at a very young age: A study from the FranceCoag network	4
Haemophilia Infants Gross Motor Development: Comparisons With Full‐Term and Preterm Infants of the Same Nationality	4
Haemophilia‐Related Pain: A Bibliometric and Content Analysis of Research Trends and Key Themes	4
Assay of Efanesoctocog Alfa in 200 Centres: Data From Collaborative NEQAS BC (United Kingdom) and ECAT (Netherlands) Exercise Autumn 2024	4